Pictet Asset Management
KYTX icon

Pictet Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

Pictet Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-86,115
Closed -$646K – 2055
2024
Q2 		$646K Sell
86,115
-13,885
-14% -$212K ﹤0.01% 1171
2024
Q1 		$2.48M Buy
+100,000
New +$2.79M ﹤0.01% 861

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pictet Asset Management's KYTX Position: Q3 2024 in Review

Pictet Asset Management sold out of Kyverna Therapeutics (KYTX) in Q3 2024, closing a stake of 86,115 shares — an estimated $646K sold.

Pictet Asset Management first reported a position in KYTX in Q1 2024 and held it in 2 quarters. The position peaked at $2.48M in Q1 2024. 94 funds tracked by Wall St. Rank hold KYTX as of Q3 2024.

  • Pictet Asset Management reported no remaining Kyverna Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pictet Asset Management sold 86,115 Kyverna Therapeutics shares in Q3 2024, an estimated $646K.
  • Pictet Asset Management first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 2 quarters.
  • Pictet Asset Management's Kyverna Therapeutics position peaked at $2.48M in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2024.

Based on Pictet Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.